{"id":48216,"date":"2022-09-11T14:01:37","date_gmt":"2022-09-11T12:01:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\/"},"modified":"2022-09-11T14:01:37","modified_gmt":"2022-09-11T12:01:37","slug":"biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\/","title":{"rendered":"BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference"},"content":{"rendered":"
\n

NESS ZIONA, Israel–(BUSINESS WIRE)–BiomX Inc. (NYSE American: PHGE) (\u201cBiomX\u201d or the \u201cCompany\u201d), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.\n<\/p>\n

<\/a><\/p>\n\n\n\n\n\n\n
\n

\n\u00a0\n<\/p>\n

\nH.C Wainwright Global Investment Conference \u2013 September 12-14, 2022<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nDate & Time:\n<\/p>\n<\/td>\n

\n

\nMonday, September 12, 7:00 AM EST (Available on Demand)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPresenter:\n<\/p>\n<\/td>\n

\n

\nJonathan Solomon\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nConference registration:\n<\/p>\n<\/td>\n

\n

\nLink<\/a>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nWebcasts of presentations will also be accessible through the Investors section of the Company\u2019s website at https:\/\/ir.biomx.com\/news-events\/ir-calendar<\/a>. Following the events, the webcasts will be archived on the BiomX website.\n<\/p>\n

\nAbout BiomX Inc.<\/b>\n<\/p>\n

\nBiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.biomx.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nBiomX Contacts<\/b>
Investor Relations:
\n
LifeSci Advisors, LLC
\n
John Mullaly
\n
(617)-698-9253
\n
jmullaly@lifesciadvisors.com<\/a>\n<\/p>\n

\nBiomX, Inc.
\n
Anat Primovich
\n
Corporate Project Manager
\n
+972 (50) 697-7228
\n
anatp@biomx.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NESS ZIONA, Israel–(BUSINESS WIRE)–BiomX Inc. (NYSE American: PHGE) (\u201cBiomX\u201d or the \u201cCompany\u201d), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. \u00a0 H.C … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48216","6":"format-standard","7":"category-industry"},"yoast_head":"\nBiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NESS ZIONA, Israel–(BUSINESS WIRE)–BiomX Inc. (NYSE American: PHGE) (\u201cBiomX\u201d or the \u201cCompany\u201d), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. \u00a0 H.C ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-11T12:01:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220911005046\/en\/1567738\/21\/final_biomx_logo-01.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference\",\"datePublished\":\"2022-09-11T12:01:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\\\/\"},\"wordCount\":206,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220911005046\\\/en\\\/1567738\\\/21\\\/final_biomx_logo-01.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\\\/\",\"name\":\"BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220911005046\\\/en\\\/1567738\\\/21\\\/final_biomx_logo-01.jpg\",\"datePublished\":\"2022-09-11T12:01:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220911005046\\\/en\\\/1567738\\\/21\\\/final_biomx_logo-01.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220911005046\\\/en\\\/1567738\\\/21\\\/final_biomx_logo-01.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference - Pharma Trend","og_description":"NESS ZIONA, Israel–(BUSINESS WIRE)–BiomX Inc. (NYSE American: PHGE) (\u201cBiomX\u201d or the \u201cCompany\u201d), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. \u00a0 H.C ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-11T12:01:37+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220911005046\/en\/1567738\/21\/final_biomx_logo-01.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference","datePublished":"2022-09-11T12:01:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\/"},"wordCount":206,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220911005046\/en\/1567738\/21\/final_biomx_logo-01.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\/","url":"https:\/\/pharma-trend.com\/en\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\/","name":"BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220911005046\/en\/1567738\/21\/final_biomx_logo-01.jpg","datePublished":"2022-09-11T12:01:37+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220911005046\/en\/1567738\/21\/final_biomx_logo-01.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220911005046\/en\/1567738\/21\/final_biomx_logo-01.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/biomx-to-present-at-h-c-wainwright-24th-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48216"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48216\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}